Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study

BACKGROUND: A randomized, controlled, phase 3b study (ALPINE) evaluated efficacy and safety of a 2-month formulation of aripiprazole lauroxil (AL) using a 1-day initiation regimen in patients hospitalized for an acute exacerbation of schizophrenia. Paliperidone palmitate (PP) was used as an active c...

Descripción completa

Detalles Bibliográficos
Autores principales: Nasrallah, Henry A., Weiden, Peter J., Walling, David P., Du, Yangchun, Yao, Baiyun, Yagoda, Sergey, Claxton, Amy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501701/
https://www.ncbi.nlm.nih.gov/pubmed/34625041
http://dx.doi.org/10.1186/s12888-021-03420-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501701/
https://www.ncbi.nlm.nih.gov/pubmed/34625041
http://dx.doi.org/10.1186/s12888-021-03420-x

Ejemplares similares